Zegerid sales force
This article was originally published in The Tan Sheet
Executive Summary
Santarus looks to build commercial presence for its proton pump inhibitor Zegerid with a sales force expansion announced Oct. 24. Santarus and Schering-Plough announced plans to switch the product from Rx to OTC earlier this month (1"The Tan Sheet" Oct. 23, 2006, p. 3). Approximately 150 sales representatives are expected to be added to the team, which will bring the total number of first detail sales reps to over 500, the firm says. Weekly prescriptions have been growing by 135% since the launch of Zegerid capsules, according to President and CEO Gerals Proehl. "Moreover, our experience indicates that the frequency in delivering a consistent message about Zegerid's clinical benefits is key to increasing awareness and positively impacting physician prescribing behavior," he added. The new sales reps are anticipated to be trained and in place by the end of the first quarter of 2007, with the help of a contract sales organization...
You may also be interested in...
Zegerid May Bring Quick Heartburn Relief To Market Under Santarus/S-P deal
Immediate-release delivery will give Santarus' proton pump inhibitor Zegerid (omeprazole/sodium bicarbonate) an edge against Prilosec OTC in the heartburn market if the firm can pull off a planned Rx-to OTC switch
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.